๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects

โœ Scribed by Chang-Koo Shim; Jae-Sun Hong

Book ID
102406146
Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
489 KB
Volume
78
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics of ketotiffn after oral
Pharmacokinetics of ketotiffn after oral administration to healthy male subjects
โœ Dr A. Grahnรฉn; A. Lรถnnebo; O. Beck; S-ร… Eckernรคs; B. Dahlstrรถm; B. Lindstrรถm ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 406 KB ๐Ÿ‘ 2 views

## Abstract The pharmacokinetics of 2 mg ketotifen from four different oral dosage forms were examined in two randomized, balanced crossโ€over studies. Forty healthy male subjects participated. Each of 20 subjects received two capsule formulations and each of the other 20 subjects received two syrup

Human dolasetron pharmacokinetics: II Ab
Human dolasetron pharmacokinetics: II Absorption and disposition following single-dose oral administration to normal male subjects
โœ Harold Boxenbaum; Todd Gillespie; Kathleen Heck; William Hahne ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 485 KB ๐Ÿ‘ 2 views

## Abstract Dolasetron is a 5โ€hydroxytryptamine antagonist active at type III receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. A previous study demonstrated that following intravenous administration to healthy

Pharmacokinetics of dolasetron following
Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects
โœ Ajit Shah; Robert Lanman; Vijay Bhargava; Scott Weir; William Hahne ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 561 KB

Dolasetron, AnzemetTM, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced metabolite of dolasetron has been identified in human plasma and is probably responsible for the majority of the antiemetic activity. This study evaluated the pharmacokin